<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Endocrine therapy resistant, hormone receptor-positive, HER2-negative advanced breast cancer</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Endocrine therapy resistant, hormone receptor-positive, HER2-negative advanced breast cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Endocrine therapy resistant, hormone receptor-positive, HER2-negative advanced breast cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anne F Schott, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel F Hayes, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 31, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2191620277"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer-related death among females worldwide [<a href="#rid1">1</a>]. Despite the gains in early detection, up to 5 percent of individuals diagnosed with breast cancer in the United States have metastatic disease at the time of first presentation, designated "de novo"<em> </em>metastases. In addition, up to 30 percent of individuals with early-stage, non-metastatic breast cancer at diagnosis will develop distant metastatic disease [<a href="#rid2">2</a>]. Although metastatic breast cancer is not curable, meaningful improvements in survival have been seen, coincident with the introduction of newer systemic therapies [<a href="#rid3">3-5</a>].</p><p>In this topic, we will use the terms "woman/en" or "patient" to describe genetic females. However, we recognize that not all people with breasts identify as female, and we encourage the reader to consider transgender and gender-nonbinary individuals as part of this larger group.</p><p>This topic will focus on the approach to chemotherapy in individuals with hormone receptor-positive advanced breast cancer. More recently, a subset of hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative cancers have been defined to have HER2 "low" disease. Chemotherapy choice in this group is also included in this topic.</p><p>It should be noted that many of the early trials (initiated prior to 2001) referenced in this topic enrolled patients with both hormone receptor-positive, HER2-negative cancers and hormone receptor-negative, HER2-negative cancers (triple-negative breast cancer [TNBC]). Some also included a minority of patients with HER2-positive disease. These entities continue to evolve; for example, given the benefits of <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> deruxtecan in patients without highly over-expressed HER2, these definitions will need to be refined. Regardless, the discussions and recommendations in this topic are focused on patients with ER-positive disease, defined by American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines as ≥1 percent positive cells by immunohistochemical staining [<a href="#rid6">6-9</a>].</p><p>A detailed discussion on the approach to individuals with TNBC, and those with HER2-positive disease, is found elsewhere. Additionally, a general overview of the approach to metastatic breast cancer, endocrine therapy for hormone receptor-positive metastatic breast cancer, HER2-directed agents and other molecularly targeted therapy, and breast cancer in men are reviewed separately. In addition, commonly used treatment regimens used in the treatment of breast cancer are also compiled in a separate topic.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/14227.html" rel="external">"ER/PR negative, HER2-negative (triple-negative) breast cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/767.html" rel="external">"Overview of the approach to metastatic breast cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/778.html" rel="external">"Treatment for hormone receptor-positive, HER2-negative advanced breast cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15749.html" rel="external">"Systemic treatment for HER2-positive metastatic breast cancer"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/779.html" rel="external">"Breast cancer in men"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/85677.html" rel="external">"Treatment protocols for breast cancer"</a>.)</p><p></p><p class="headingAnchor" id="H117388102"><span class="h1">GOALS OF TREATMENT AND DEFINITIONS</span><span class="headingEndMark"> — </span>The goals of treatment of metastatic breast cancer are to prolong survival and improve quality of life by reducing cancer-related symptoms. In order to achieve these goals, an individualized approach is needed since no one strategy can be applied for all individuals.</p><p>Although endocrine therapy is typically employed for patients with hormone-receptor positive, HER2-negative breast cancer (particularly in the initial treatment setting), cytotoxic chemotherapy may be preferred in select patients with symptomatic hormone receptor-positive breast cancer, who have the following presentations [<a href="#rid10">10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endocrine therapy resistant disease</strong> – Those who experience rapid disease progression following at least one endocrine therapy (ie, endocrine-resistant disease)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Endocrine therapy refractory disease</strong> – Patients with disease that has progressed on multiple lines of endocrine therapy</p><p></p><p>Further discussion on the choice between endocrine therapy and chemotherapy is found elsewhere. (See  <a class="medical medical_review" href="/d/html/767.html" rel="external">"Overview of the approach to metastatic breast cancer", section on 'Choosing between endocrine therapy and chemotherapy'</a>.)</p><p>The administration of endocrine therapy for patients with hormone receptor-positive metastatic breast cancer is covered separately. (See  <a class="medical medical_review" href="/d/html/778.html" rel="external">"Treatment for hormone receptor-positive, HER2-negative advanced breast cancer"</a> and  <a class="medical medical_review" href="/d/html/767.html" rel="external">"Overview of the approach to metastatic breast cancer"</a>.)</p><p class="headingAnchor" id="H454788364"><span class="h1">FACTORS INFLUENCING CHEMOTHERAPY CHOICE</span><span class="headingEndMark"> — </span>For patients in whom chemotherapy is recommended, the choice between a single agent or a combination regimen, and the selection of a specific therapy, should take into account several factors in an effort to individualize therapy as much as possible  (<a class="graphic graphic_algorithm graphicRef139772" href="/d/graphic/139772.html" rel="external">algorithm 1</a>).</p><p>Because of the availability of many agents to treat metastatic breast cancer, there is no ideal sequence of treatments that can be applied to all patients. It is likely that patients with metastatic breast cancer will receive many (if not all) of these treatments throughout the course of their disease. However, below we illustrate the principles that can guide the choice of therapy in the first- or later-line setting, given that currently available systemic treatments for metastatic breast cancer are not curative, we encourage participation in well-designed clinical trials.</p><p class="headingAnchor" id="H454788372"><span class="h2">Tumor burden</span><span class="headingEndMark"> — </span>Tumor burden (the extent of disease detected on imaging or clinical examination and/or the presence of tumor-related symptoms) can impact on whether single-agent chemotherapy or a combination regimen is administered:</p><p class="bulletIndent1"><span class="glyph">●</span>We prefer the sequential use of single-agent chemotherapy, especially for patients with a limited tumor burden and/or limited or minimal cancer-related symptoms. Sequential single-agent treatment is often less toxic and results in similar overall survival compared with combination chemotherapy [<a href="#rid11">11</a>]. (See <a class="local">'Initial chemotherapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For select patients, we favor the use of a combination regimen rather than a single agent because combination therapy results in a higher response rate, which may justify the risks of treatment [<a href="#rid12">12</a>]. Appropriate patients include those with symptomatic disease due to the location of specific metastatic lesions (eg, right upper quadrant pain due to expanding liver metastases, or dyspnea related to diffuse lung metastases) and a large tumor burden, as well as those with rapidly progressive disease. (See <a class="local">'Combination versus single agent chemotherapy'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with brain metastases, systemic treatment may not be required if there is no evidence of systemic disease. In the presence of systemic disease, treatment of both the central nervous system and systemic disease should be individualized. (See  <a class="medical medical_review" href="/d/html/775.html" rel="external">"Brain metastases in breast cancer"</a>.)</p><p></p><p class="headingAnchor" id="H454788452"><span class="h2">General health status</span><span class="headingEndMark"> — </span>Treatment decisions should take into account the overall health status of the patient, which can be gauged by the performance status  (<a class="graphic graphic_table graphicRef57945" href="/d/graphic/57945.html" rel="external">table 1</a>) or, in the case of older individuals, a comprehensive geriatric analysis. (See  <a class="medical medical_review" href="/d/html/2808.html" rel="external">"Comprehensive geriatric assessment for patients with cancer"</a> and  <a class="medical medical_review" href="/d/html/761.html" rel="external">"Treatment of metastatic breast cancer in older women"</a>.)</p><p>For patients in whom a <strong>single agent</strong> is recommended, an understanding of the patient's health status also may influence the appropriate selection of agents. As examples (see <a class="local">'Initial chemotherapy'</a> below):</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a history of cardiac disease or heart failure and those who are felt to be at a greater risk for cardiac injury (eg, older adult patients) should not be treated with an anthracycline. There are multiple appropriate alternatives (eg, <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> or <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with symptomatic peritoneal metastases, those who have difficulty swallowing pills, or those who are not able to follow instructions required to use a daily regimen may not be good candidates for oral therapies (eg, <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients at risk for hyperglycemia (eg, patients with diabetes) and those who cannot tolerate steroids for whatever reason may derive more of a benefit from agents that do not require steroid premedication (eg, use of nanoparticle albumin-bound <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> [<a class="drug drug_general" data-topicid="10159" href="/d/drug information/10159.html" rel="external">nabpaclitaxel</a>] instead of paclitaxel).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a poor performance status or those with significant competing comorbidities may not benefit from treatment at all, especially if they have well-controlled symptoms and a higher risk of dying from a cause other than breast cancer. Therefore, the benefits and risks of single-agent therapy should be balanced against overall prognosis.</p><p></p><p class="headingAnchor" id="H454788459"><span class="h2">Prior treatment and toxicities</span><span class="headingEndMark"> — </span>For the patient who has been previously exposed to chemotherapy (eg, as adjuvant treatment or previous therapy for metastatic breast cancer), there is no optimal sequence of administration of chemotherapy agents used to treat metastatic breast cancer. In general, treatment with chemotherapy drugs of different classes (non-cross resistant agents) may result in a higher probability of response, especially if disease progression occurred within six months following the previously administered regimen [<a href="#rid13">13</a>]. However, the treatment history (ie, agents used and any previous toxicity experienced or persisting) should be reviewed to help inform the choice of a subsequent regimen. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients who received <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> or <a class="drug drug_general" data-topicid="8663" href="/d/drug information/8663.html" rel="external">epirubicin</a> in the adjuvant setting, even years previously, may not be good candidates for repeat anthracycline therapy due to increasing risk of cardiac toxicity at higher cumulative doses. (See <a class="local">'Anthracyclines'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with pancytopenia due to myelophthisic disease, or with a history of myelosuppression with prior therapy that resulted in dose modification or treatment delay may not be good candidates for agents or schedules with significant myelotoxicity risks (eg, every-three-week <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a>). In these situations, single-agent treatment using a weekly anthracycline, <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>, or a weekly taxane may be more appropriate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with baseline or a history of serious (grade 3/4) neuropathy may not be good candidates for microtubulin-directed agents (eg, taxanes, <a class="drug drug_general" data-topicid="8909" href="/d/drug information/8909.html" rel="external">ixabepilone</a>, <a class="drug drug_general" data-topicid="16096" href="/d/drug information/16096.html" rel="external">eribulin</a>, or <a class="drug drug_general" data-topicid="10046" href="/d/drug information/10046.html" rel="external">vinorelbine</a>), or for <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>. These patients are appropriate candidates for <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>, <a class="drug drug_general" data-topicid="126410" href="/d/drug information/126410.html" rel="external">fam-trastuzumab deruxtecan</a> (T-DxD), <a class="drug drug_general" data-topicid="127999" href="/d/drug information/127999.html" rel="external">sacituzumab govitecan</a>, anthracyclines, or other agents.</p><p></p><p class="headingAnchor" id="H961692840"><span class="h2">BRCA1 or 2 mutation carriers</span><span class="headingEndMark"> — </span>Patients with known breast cancer susceptibility gene (<em>BRCA</em>) mutations may specifically derive benefit from platinum agents. In a phase II study, single-agent <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> yielded an 80 percent response rate in <em>BRCA1</em> mutation-associated metastatic breast cancer [<a href="#rid14">14</a>].</p><p>For patients with metastatic HER2-negative breast cancer and germline <em>BRCA</em> mutations, the oral inhibitor of poly(ADP-ribose) polymerase (PARP) <a class="drug drug_general" data-topicid="98761" href="/d/drug information/98761.html" rel="external">olaparib</a> has shown efficacy. For such patients, chemotherapy versus PARP inhibition is discussed in more detail elsewhere. (See  <a class="medical medical_review" href="/d/html/767.html" rel="external">"Overview of the approach to metastatic breast cancer", section on 'Special considerations'</a>.)</p><p class="headingAnchor" id="H454788473"><span class="h2">Patient preferences</span><span class="headingEndMark"> — </span>Patient preferences help to individualize treatment plans for metastatic breast cancer.</p><p>For example:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients who prefer less frequent visits for intravenous treatments may opt for treatment administered every three weeks, rather than weekly. Appropriate regimens that can be administered every three weeks include single-agent <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a>, T-DxD, and liposomal <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who prefer a low risk of alopecia may want to avoid taxanes and anthracyclines (where the risk of alopecia is close to 90 percent). Options in this circumstance include agents with a lower risk of alopecia, such as <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> (less than 10 percent), <a class="drug drug_general" data-topicid="10135" href="/d/drug information/10135.html" rel="external">pegylated liposomal doxorubicin</a> (less than 20 percent), and <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> (up to 15 percent). Alternatively, such individuals may prefer regimens given every three weeks, as discussed above, used with a scalp cooling device to reduce hair loss. (See  <a class="medical medical_review" href="/d/html/1156.html" rel="external">"Alopecia related to systemic cancer therapy", section on 'Scalp hypothermia (scalp cooling)'</a> and <a class="local">'Single-agent chemotherapy'</a> below and <a class="local">'Other agents'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients who prefer less intrusion on their lifestyle may opt for an orally administered agent, such as <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>, rather than treatments that require intravenous infusion. (See <a class="local">'Capecitabine'</a> below.)</p><p></p><p class="headingAnchor" id="H2993542"><span class="h1">INITIAL CHEMOTHERAPY</span><span class="headingEndMark"> — </span>There are a number of agents with activity in metastatic breast cancer. Because the taxanes and <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> are most commonly administered, especially in the first-line treatment of metastatic breast cancer, they are presented first.</p><p>In general, we prefer not to administer chemotherapy with endocrine therapy for individuals with hormone receptor-positive disease in order to minimize side effects, including an increased risk of thromboembolic events [<a href="#rid15">15</a>]. In addition, a 1998 meta-analysis showed that combining these treatments was not more effective than the use of chemotherapy alone [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H2004153057"><span class="h2">Preferred options</span></p><p class="headingAnchor" id="H196667394"><span class="h3">Taxanes</span><span class="headingEndMark"> — </span>Taxanes are among the most active agents for metastatic breast cancer. Agents in this class include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Docetaxel</strong> – <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">Docetaxel</a> can be administered every three weeks (80 to 100 mg/m<sup>2</sup>) or weekly (30 to 40 mg/m<sup>2</sup> weekly for three weeks followed by one week off) [<a href="#rid17">17</a>]. Of these schedules, we prefer dosing every three weeks based on the results of a randomized trial in the adjuvant setting that showed every-three-week dosing results in an improvement in disease-free survival compared with weekly dosing [<a href="#rid18">18</a>]. Docetaxel is associated with a significant risk of fluid retention, which is reduced by premedication with <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Paclitaxel</strong> – <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">Paclitaxel</a> can be administered weekly (80 to 100 mg/m<sup>2</sup> on days 1, 8, and 15 of a 28-day cycle) or every three weeks (175 mg/m<sup>2</sup>) [<a href="#rid17">17,18,20</a>]. Whenever possible, we prefer weekly scheduling based on the results of a 2010 meta-analysis, which showed that compared with every-three-week treatment, weekly administration of paclitaxel resulted in an improvement in overall survival (OS) in patients with advanced breast cancer (hazard ratio [HR] 0.78, 95% CI 0.67-0.89) [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1">It should be noted that patients treated with <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> are at risk for infusion reactions as a result of the composition of paclitaxel, which is mixed with a solubilizer. At most institutions, steroids (eg, <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> 20 mg the night before and morning of infusion), H1 blockers (eg, <a class="drug drug_general" data-topicid="9369" href="/d/drug information/9369.html" rel="external">diphenhydramine</a> 25 mg), and H2 blockers (eg, <a class="drug drug_general" data-topicid="8436" href="/d/drug information/8436.html" rel="external">famotidine</a> 10 mg) are administered, although these can often be discontinued if the first two or three doses are tolerated. However, the schedule and administration of premedications varies by institution.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nabpaclitaxel</strong> – <a class="drug drug_general" data-topicid="10159" href="/d/drug information/10159.html" rel="external">Nabpaclitaxel</a> has activity in metastatic breast cancer similar to other taxanes [<a href="#rid21">21-23</a>]. It may be of particular benefit to patients who are at risk for hyperglycemia, those who cannot tolerate steroids, or those with a history of infusion reactions to <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a>. Nabpaclitaxel has a lower risk of infusion reactions compared with other taxanes, which negates the requirement for steroid premedications and the risk of steroid-induced hyperglycemia.</p><p></p><p class="headingAnchor" id="H196667401"><span class="h4">Comparing taxanes</span><span class="headingEndMark"> — </span>For patients in whom a taxane is indicated, the choice between taxanes can be based on their comparative safety profiles and patient preferences regarding scheduling of treatments. For example:</p><p class="bulletIndent1"><span class="glyph">●</span>The risks of neuropathy and myalgia are greater with <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> than with <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a>.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">Paclitaxel</a> can be administered in the setting of mild-moderate hepatic dysfunction. By contrast, <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> should not be administered in this context.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">Docetaxel</a> given every three weeks is the more myelosuppressive taxane agent. Risks from docetaxel also include febrile neutropenia, edema, and gastrointestinal toxicities.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10159" href="/d/drug information/10159.html" rel="external">Nabpaclitaxel</a> does not require premedication with steroids, but otherwise has a toxicity profile similar to <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a>.</p><p></p><p>There are limited data comparing each of the taxanes against each other. However, they show that the activity and toxicity differ by which schedule was used (ie, weekly or every three weeks) and by agent. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">Docetaxel</a> was compared with <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> (both on a 21-day cycle) in a trial of 449 patients with advanced breast cancer that had progressed after an anthracycline-containing chemotherapy regimen. Docetaxel produced a significantly better median time to progression (TTP, 5.7 versus 3.6 months) and OS (15.4 versus 12.7 months) compared with paclitaxel [<a href="#rid24">24</a>]. However, both hematologic and nonhematologic toxicity were worse with docetaxel.</p><p></p><p class="bulletIndent1">Although this study found that every-three-week dosing of <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> is superior to the same schedule using <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a>, weekly paclitaxel (which is the preferred method of administration) has not been compared with every-three-week docetaxel in the metastatic setting.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">Paclitaxel</a> and <a class="drug drug_general" data-topicid="10159" href="/d/drug information/10159.html" rel="external">nabpaclitaxel</a> were compared as a first-line treatment (as single agents or with administration with <a class="drug drug_general" data-topicid="8683" href="/d/drug information/8683.html" rel="external">bevacizumab</a>) in a randomized phase III trial [<a href="#rid25">25</a>]. The study randomized 799 patients (44 percent who were previously treated with adjuvant paclitaxel) to bevacizumab with either weekly treatment with paclitaxel (90 mg/m<sup>2</sup>) or nabpaclitaxel (150 mg/m<sup>2</sup>) on a three week on, one week off schedule. A third arm including weekly <a class="drug drug_general" data-topicid="8909" href="/d/drug information/8909.html" rel="external">ixabepilone</a> (16 mg/m<sup>2</sup>) was closed for futility at the first interim analysis. The results for paclitaxel versus nabpaclitaxel are discussed below. (See <a class="local">'Other agents'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>No statistically significant difference in progression-free survival between <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> and <a class="drug drug_general" data-topicid="10159" href="/d/drug information/10159.html" rel="external">nabpaclitaxel</a> (11 versus 9.3 months, respectively; HR 1.20; 95% CI 1.00-1.40).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>No statistically significant difference in OS between <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> and <a class="drug drug_general" data-topicid="10159" href="/d/drug information/10159.html" rel="external">nabpaclitaxel</a> (26.5 versus 23.5 months, respectively, HR 1.17, 95% CI 0.92-1.47).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A higher rate of serious toxicity (grade 3 or higher) in the <a class="drug drug_general" data-topicid="10159" href="/d/drug information/10159.html" rel="external">nabpaclitaxel</a> versus <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> arms, including sensory neuropathy (27 versus 18 percent, respectively) and hematologic toxicity (55 versus 22 percent).</p><p></p><p class="headingAnchor" id="H196667468"><span class="h3">Capecitabine</span><span class="headingEndMark"> — </span>Single-agent <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> (1000 to 1250 mg/m<sup>2</sup> twice daily for 14 days followed by seven days of rest) is a frequent choice as a first-line treatment for metastatic breast cancer, particularly in patients with bone-predominant, estrogen receptor-positive metastatic disease who have progressed following two trials of endocrine therapy, at least one of which was in combination in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor. An alternative schedule of 1500 mg twice daily on days 1 to 7 and 15 to 21 of a 28-day schedule has shown similar outcomes in a randomized trial, with less toxicity [<a href="#rid26">26</a>].</p><p>In addition, <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> also appears to cross the blood brain barrier better than some agents and may be a good consideration in patients with a history of central nervous system metastases [<a href="#rid27">27</a>]. (See  <a class="medical medical_review" href="/d/html/775.html" rel="external">"Brain metastases in breast cancer"</a>.)</p><p><a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">Capecitabine</a> is a prodrug of the anti-metabolite <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a>. It is orally available, and unlike many agents used in the treatment of breast cancer, it causes very little alopecia or neuropathy. Its primary toxicities are hand-foot syndrome and diarrhea, and it can be used in settings of mild hepatic dysfunction. The dose of capecitabine must be adjusted, however, in the presence of mild renal dysfunction. The benefit of capecitabine was shown in two multicenter single-arm phase II trials [<a href="#rid28">28,29</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In one study, 126 patients were treated with <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> (1250 mg/m<sup>2</sup> dose). The median TTP was 5 months and the overall response rate (ORR) was 28 percent. Median OS was 15 months [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a second study, 95 individuals were randomly assigned to <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> or <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, plus <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> (CMF). Capecitabine resulted in a higher ORR compared with CMF (30 versus 16 percent, respectively). The median TTP was similar (4 versus 3 months) but capecitabine resulted in a slightly longer median OS (20 versus 17 months) [<a href="#rid29">29</a>].</p><p></p><p><a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">Capecitabine</a> may cause excess toxicity in the case of dihydropyridine dehydrogenase (DPYD) deficiency, which is present in approximately 5 percent of the population. Pre-emptive genotyping has not been routinely implemented into standard clinical practice due to the low carrier frequency and genotyping costs (although there has been an increasing call to do so [<a href="#rid30">30,31</a>]). If a patient is known to have a germline DPYD polymorphism that would lead to decreased enzymatic activity, either an alternative agent or dose reduction should be considered [<a href="#rid32">32,33</a>].</p><p class="headingAnchor" id="H4046302494"><span class="h1">MONITORING THERAPY</span><span class="headingEndMark"> — </span>The ongoing evaluation of patients during therapy (including timing of imaging and the selection of imaging modality) should be individualized according to patient and provider preferences. Further discussion on the monitoring of patients with metastatic breast cancer is covered separately. (See  <a class="medical medical_review" href="/d/html/767.html" rel="external">"Overview of the approach to metastatic breast cancer", section on 'Monitoring therapy'</a>.)</p><p>Careful assessment for response to treatment requires serial clinical examination, repeat laboratory evaluation (including tumor markers), and radiographic imaging. Although there is no standard schedule for evaluation during treatment, a reasonable approach would be as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>History and physical examination prior to the start of each treatment cycle (ie, day one of a new 21- or 28-day treatment cycle).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Repeat imaging studies (using the same imaging modality throughout) after completion of two cycles of therapy (ie, after cycle two, cycle four, etc).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Serial assay for serum tumor markers (eg, cancer antigen [CA] 15-3, CA 27.29, and/or carcinoembryonic antigen) if they were elevated at baseline. If performed, we typically reevaluate them at the beginning of each treatment cycle.</p><p></p><p class="headingAnchor" id="H953598522"><span class="h1">DEFINITION OF TREATMENT FAILURE</span><span class="headingEndMark"> — </span>In our own practice, we monitor for treatment failure by taking into account serial changes in or appearance of new symptoms, abnormal liver function tests, circulating tumor markers, and evidence of disease progression based on serial imaging. Some criteria that we use to define treatment failure include any of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Clinical deterioration during treatment (ie, increasing or new disease related symptoms, intolerable treatment toxicities, declining performance status)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Evidence of new metastases</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increasing size of previously documented metastatic lesions</p><p></p><p class="headingAnchor" id="H1413042756"><span class="h2">RECIST criteria</span><span class="headingEndMark"> — </span>The primary role of Response Evaluation Criteria in Solid Tumors (RECIST 1.1) is to standardize the reporting of results on clinical trials  (<a class="graphic graphic_table graphicRef57181" href="/d/graphic/57181.html" rel="external">table 2</a>) [<a href="#rid34">34</a>]. RECIST primarily applies to imaging of metastatic disease, and it encompasses two of the three reasons for treatment failure.</p><p>According to RECIST, disease progression on imaging is defined as any of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>A 20 percent or more increase in the sum of measurable target lesions compared with the smallest sum previously recorded</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The appearance of any new lesions</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Worsening of existing non-target lesions, for example, bone metastases</p><p></p><p class="headingAnchor" id="H3891364114"><span class="h1">SUBSEQUENT LINE OPTIONS</span></p><p class="headingAnchor" id="H4286059080"><span class="h2">HER2-"low" tumors</span></p><p class="headingAnchor" id="H1493531147"><span class="h3">Fam-trastuzumab deruxtecan (T-DxD)</span><span class="headingEndMark"> — </span>For patients with hormone receptor-positive, endocrine-refractory tumors that are HER2 immunohistochemistry (IHC) 1+ or 2+ and in situ hybridization (ISH) negative, <a class="drug drug_general" data-topicid="126410" href="/d/drug information/126410.html" rel="external">fam-trastuzumab deruxtecan</a> (T-DxD) has been found to improve progression-free survival (PFS) and overall survival (OS) compared with other chemotherapy regimens in the second or later lines [<a href="#rid35">35</a>]. We offer T-DxD for patients with hormone receptor-positive, HER2-low metastatic breast cancer after progression on <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> and/or taxane in the metastatic setting. For patients with severe underlying lung disease, T-DxD may not be appropriate due to the risk of pneumonitis with this drug.</p><p>T-DxD is an antibody-drug conjugate consisting of a <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a> targeting molecule conjugated to deruxtecan, a topoisomerase-1 inhibitor. It was originally approved for HER2-positive metastatic breast cancer.</p><p>DESTINY-Breast04 was a phase III trial involving patients with HER2-low metastatic breast cancer who had received one or two previous lines of chemotherapy. Low expression of HER2 was defined as a score of 1+ on IHC analysis or as an IHC score of 2+ and negative results on ISH [<a href="#rid35">35</a>]. Patients were randomly assigned in a 2:1 ratio to receive T-DxD or the clinician's choice of chemotherapy. This trial included both patients with hormone receptor positive and those with hormone receptor negative tumors, and the overall results are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/767.html" rel="external">"Overview of the approach to metastatic breast cancer", section on 'HER2-low tumors'</a>.)</p><p>Among the 494 patients with hormone receptor-positive disease, the median PFS was 10.1 months in the T-DxD group and 5.4 months in the clinician's choice group (hazard ratio [HR] for disease progression or death 0.51, 95% CI, 0.40-0.64), and OS was 23.9 months and 17.5 months, respectively (HR for death 0.64, 95% CI, 0.48-0.86).</p><p>Adverse events of ≥grade 3 occurred in 53 percent of the patients who received T-DxD and 67 percent of those who received the clinician's choice of chemotherapy. Drug-related interstitial lung disease or pneumonitis occurred in 12 percent of the patients who received T-DxD; 0.8 percent had grade 5 events.</p><p>T-DxD has shown activity in brain metastases in HER positive metastatic breast cancer, and may be a good option in patients with a history of central nervous system metastases. (See  <a class="medical medical_review" href="/d/html/775.html" rel="external">"Brain metastases in breast cancer"</a> and  <a class="medical medical_review" href="/d/html/775.html" rel="external">"Brain metastases in breast cancer", section on 'Fam-trastuzumab deruxtecan'</a>.)</p><p>The precise method to distinguish HER2 0 from 1+ after IHC staining has not been determined, and some have argued that the distinction is not biologically relevant, and that the benefit of antibody-drug conjugates in this setting is likely primarily related to the delivery of cytotoxic molecules, rather than the blockade of the HER2 pathway [<a href="#rid36">36</a>]. Indeed, in one phase II study, patients with HER2-low and HER2-nonexpressing cancers experienced similar objective response rates to T-DxD (38 and 30 percent, respectively, versus 71 percent among HER2-overexpressing cancers) [<a href="#rid37">37</a>].</p><p>In the DESTINY-Breast04 trial, all tissues were stained using a single monoclonal antibody (Mab 4D5) and were read in a central laboratory. The concordance among pathologist to distinguish 0 from 1+ is reported to be poor [<a href="#rid38">38</a>]. Efforts to use a more quantitative and accurate method to assess HER2 have been reported but are not yet validated for routine clinical use [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H2464603691"><span class="h3">Upon progression on T-DxD</span></p><p class="headingAnchor" id="H866486700"><span class="h4">Single-agent chemotherapy</span><span class="headingEndMark"> — </span>For patients with HER2-low tumors who have experienced progression on T-DxD, there is no standard approach. At this time, it is not known whether patients with HER2-low metastatic breast cancer who have progressed on T-DxD will have a good response to <a class="drug drug_general" data-topicid="127999" href="/d/drug information/127999.html" rel="external">sacituzumab govitecan</a> (SG), since both drugs have a topoisomerase-1 cytotoxic agent. In our practice, we do not routinely sequence these drugs, and instead go to a non-cross resistant drug. (See <a class="local">'Preferred options'</a> above and <a class="local">'Later line (or alternative) single-agent chemotherapy options'</a> below.)</p><p class="headingAnchor" id="H465478785"><span class="h2">Other HER2-negative cancers (HER2 "0")</span></p><p class="headingAnchor" id="H677316930"><span class="h3">Single-agent chemotherapy</span><span class="headingEndMark"> — </span>For patients who have progressed on a taxane and <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> and have HER2 0 tumors, a subsequent line of single-agent chemotherapy is appropriate, provided that the patient remains a candidate for therapy. (See <a class="local">'Preferred options'</a> above and <a class="local">'Later line (or alternative) single-agent chemotherapy options'</a> below.)</p><p class="headingAnchor" id="H3115691830"><span class="h3">Upon progression on two prior chemotherapies</span></p><p class="headingAnchor" id="H222501761"><span class="h4">Sacituzumab govitecan</span><span class="headingEndMark"> — </span>SG has received approval by the US Food and Drug Administration (FDA) for patients with unresectable locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting [<a href="#rid40">40,41</a>]. We consider use of SG in our hormone receptor-positive, HER2 0 (not low) metastatic breast cancer patients after progression on endocrine therapy, as well as <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> <strong>and</strong> taxanes in the metastatic setting. Although SG is also an option in hormone receptor-positive, HER2-low tumors after progression on two prior lines of chemotherapy, patients with such cancers are typically offered T-DxD earlier in their treatment course, and therefore may not be good candidates for further treatment with a topoisomerase-1 cytotoxic agent. If they have not received T-DxD, SG is an appropriate option after progression on two chemotherapies.</p><p>SG is an antibody-drug conjugate consisting of an antibody targeting TROP-2, conjugated to SN-38, a topoisomerase-1 inhibitor. It was originally approved for triple-negative metastatic breast cancer. (See  <a class="medical medical_review" href="/d/html/14227.html" rel="external">"ER/PR negative, HER2-negative (triple-negative) breast cancer", section on 'Sacituzumab govitecan'</a>.)</p><p>TROPiCS-02 was a randomized trial involving patients with metastatic or locally recurrent inoperable hormone receptor-positive/HER2-negative breast cancer that progressed after at least one endocrine therapy, a cyclin-dependent kinase (CDK) 4/6 inhibitor in any setting, and at least two, but no more than four, lines of chemotherapy for metastatic disease [<a href="#rid42">42,43</a>]. Prior treatment must have included a taxane in either the neo/adjuvant or advanced disease setting. Patients were randomly assigned in a 1:1 ratio to receive SG or the clinician's choice of chemotherapy (choices included <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>, <a class="drug drug_general" data-topicid="10046" href="/d/drug information/10046.html" rel="external">vinorelbine</a>, <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a>, or <a class="drug drug_general" data-topicid="16096" href="/d/drug information/16096.html" rel="external">eribulin</a>).</p><p>Among 543 patients, the median PFS was 5.5 months in the SG group and 4.0 months in the clinician's choice group (HR for disease progression or death 0.66, 95% CI 0.53-0.83) [<a href="#rid44">44</a>]. In a subsequent publication with longer follow up SG resulted in a longer median OS relative to the clinician's choice group (14.4 versus 11.2 months, HR 0.79, 95% CI 0.65-0.96) [<a href="#rid45">45</a>].</p><p>Grade ≥3 treatment-emergent adverse events occurred in 74 percent on SG and 60 percent on TPC; neutropenia (51 versus 38 percent) and diarrhea (9 versus 1 percent) were most common.</p><p class="headingAnchor" id="H2266559775"><span class="h1">LATER LINE (OR ALTERNATIVE) SINGLE-AGENT CHEMOTHERAPY OPTIONS</span><span class="headingEndMark"> — </span>For patients who have progressed on initial lines of chemotherapy (or are not candidates for the agents above), others are available and have documented activity against breast cancer.</p><p class="headingAnchor" id="H3248753660"><span class="h2">Anthracyclines</span><span class="headingEndMark"> — </span>The anthracyclines are important agents for the treatment of breast cancer. However, their use in the adjuvant context often limits their application in individuals with metastatic disease. Despite this, anthracyclines may be appropriate in select patients, particularly those who were not treated with an anthracycline in the past. In addition, anthracyclines can be used in patients with mild to moderate hepatic dysfunction with dose modification.</p><p>The anthracyclines used in the treatment of metastatic breast cancer are:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">Doxorubicin</a> (60 to 75 mg/m<sup>2</sup> every three weeks, or 20 mg/m<sup>2</sup> weekly for three weeks followed by one week off) – Overall response rate (ORR) 30 to 47 percent [<a href="#rid46">46,47</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8663" href="/d/drug information/8663.html" rel="external">Epirubicin</a> (75 to 100 mg/m<sup>2</sup> every three weeks, or 20 to 30 mg/m<sup>2</sup> weekly for three weeks followed by one week off) – ORR 42 to 50 percent [<a href="#rid48">48-50</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="10135" href="/d/drug information/10135.html" rel="external">Pegylated liposomal doxorubicin</a> (PLD; 40 mg/m<sup>2</sup> every four weeks) – ORR 10 to 33 percent [<a href="#rid51">51,52</a>]</p><p></p><p class="headingAnchor" id="H4105905127"><span class="h3">Approach to managing cardiotoxicity</span><span class="headingEndMark"> — </span>One potential downside of using anthracycline regimens is the risk for cumulative cardiac toxicity, which may limit the duration of anthracycline-based therapy. The recommended lifetime cumulative dose limit of <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> hydrochloride is 450-550 mg/m<sup>2</sup>. However, for patients who are responding to treatment and otherwise are tolerating therapy, the use of <a class="drug drug_general" data-topicid="9338" href="/d/drug information/9338.html" rel="external">dexrazoxane</a> may minimize the risk of treatment-related cardiac damage. For patients treated with doxorubicin, dexrazoxane is an option after a cumulative doxorubicin dose of 300 mg/m<sup>2</sup> [<a href="#rid53">53</a>]. Further, the clinician may wish to use alternative doses and schedules than are commonly used in the adjuvant setting, such as low-dose weekly (20 mg/m<sup>2</sup>) treatment, or as a longer (24 hours) infusion.</p><p>The use of an alternative anthracycline agent, PLD also limits cardiotoxicity [<a href="#rid54">54</a>]. Although there is no dose limit of PLD, our practice is to initiate cardiac monitoring in patients with cardiac risk factors who have received &gt;450 mg/m<sup>2</sup>. We have not found it necessary to add <a class="drug drug_general" data-topicid="9338" href="/d/drug information/9338.html" rel="external">dexrazoxane</a> to PLD. (See  <a class="medical medical_review" href="/d/html/90854.html" rel="external">"Clinical manifestations, diagnosis, and treatment of anthracycline-induced cardiotoxicity"</a> and  <a class="medical medical_review" href="/d/html/107443.html" rel="external">"Risk and prevention of anthracycline cardiotoxicity"</a>.)</p><p class="headingAnchor" id="H3399843305"><span class="h3">Comparing anthracyclines</span><span class="headingEndMark"> — </span>Our preferred anthracycline in the metastatic hormone receptor-positive setting is PLD administered at 40 mg/m<sup>2</sup> every four weeks, because it appears to be equally active and less toxic compared with <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> administered every three weeks. This was shown in a trial of 509 patients with metastatic breast cancer (56 percent who had previously received anthracyclines) who were randomly assigned treatment with PLD 50 mg/m<sup>2</sup> given every four weeks or doxorubicin 60 mg/m<sup>2</sup> given every three weeks [<a href="#rid51">51</a>]. Compared with doxorubicin, PLD, resulted in:</p><p class="bulletIndent1"><span class="glyph">●</span>Slightly lower ORR (33 versus 38 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar progression-free survival (PFS; median, 6.9 versus 7.8 months) and OS (median, 21 versus 22 months; HR 0.94), though PFS measures were confounded by more frequent assessments in the every-three-week <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> arm.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A decrease in the risk of cardiotoxicity (7 versus 26 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lower rates of alopecia (20 versus 66 percent), nausea (37 versus 53 percent), vomiting (19 versus 31 percent), and neutropenia (4 versus 10).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Higher rate of plantar-plantar erythrodysesthesia (48 versus 2 percent), stomatitis (22 versus 15 percent), and mucositis (23 versus 13 percent).</p><p></p><p class="headingAnchor" id="H80261226"><span class="h2">Eribulin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="16096" href="/d/drug information/16096.html" rel="external">Eribulin</a> mesylate (1.4 mg/m<sup>2</sup> days 1 and 8 every 21 days) is derived from a marine sponge and inhibits the polymerization of tubulin and microtubules. It results in less neuropathy than other microtubule-directed agents and can be administered with dose adjustment for mild to moderate hepatic dysfunction.</p><p>The activity of <a class="drug drug_general" data-topicid="16096" href="/d/drug information/16096.html" rel="external">eribulin</a> has been demonstrated in clinical trials [<a href="#rid55">55-58</a>]. For example, in a phase III trial of 762 heavily pretreated patients randomly assigned to treatment with eribulin or other chemotherapy (based on clinician's and patient's choice), eribulin significantly improved OS (median, 13.1 versus 10.6 months) [<a href="#rid57">57</a>]. The primary toxicity with eribulin was neutropenia, with grade 3 and 4 neutropenia in 45 percent of patients, and grade 3 and 4 febrile neutropenia in 5 percent. Peripheral neuropathy was the most common adverse event leading to discontinuation of eribulin, occurring in 5 percent of patients. (See  <a class="medical medical_review" href="/d/html/2836.html" rel="external">"Overview of neurologic complications of conventional non-platinum cancer chemotherapy", section on 'Eribulin'</a>.)</p><p>Of note, a subsequent randomized trial was performed in individuals with metastatic breast cancer who had received prior anthracycline and taxane therapy with an aim to formally evaluate <a class="drug drug_general" data-topicid="16096" href="/d/drug information/16096.html" rel="external">eribulin</a> versus <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> as first-, second-, or third-line therapy [<a href="#rid56">56</a>]. Unlike the trial above, there was no difference between eribulin and capecitabine in terms of PFS (four months in each) or ORR (11 and 11.5 percent, respectively). In addition, there was no clinically meaningful difference in OS (15.9 versus 14.5 months, respectively; HR 0.88, 95% CI 0.77-1.00).</p><p class="headingAnchor" id="H2927208518"><span class="h2">Vinorelbine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10046" href="/d/drug information/10046.html" rel="external">Vinorelbine</a> is an intravenously administered agent usually dosed at 30 mg/m<sup>2</sup> on a weekly schedule (days 1 and 8 every 21 days) [<a href="#rid59">59</a>]. Vinorelbine causes little nausea, vomiting, and hair loss, and is active as a single agent (ORR 25 to 45 percent), even in heavily pretreated patients [<a href="#rid60">60-62</a>]. As it is also a microtubule-directed agent, we rarely use vinorelbine in patients who have already received <a class="drug drug_general" data-topicid="16096" href="/d/drug information/16096.html" rel="external">eribulin</a>.</p><p class="headingAnchor" id="H1158968457"><span class="h2">Other agents</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gemcitabine</strong> – Although data suggest <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> is active in combination with <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> in first-line metastatic breast cancer, gemcitabine (commonly 800 to 1000 mg/m<sup>2</sup> days 1 and 8 of a 21-day cycle) is frequently used as a single agent.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">Gemcitabine</a> appears to cross the blood brain barrier and may be a good option in patients with a history of central nervous system metastases [<a href="#rid63">63</a>]. Alopecia and gastrointestinal toxicity are mild, and its use is not associated with significant neuropathy. Gemcitabine is well tolerated and active in metastatic breast cancer, though when gemcitabine was directly compared with weekly <a class="drug drug_general" data-topicid="8663" href="/d/drug information/8663.html" rel="external">epirubicin</a> as first-line chemotherapy in individuals not previously exposed to an anthracycline, it resulted in a significantly shorter time to progressive disease and a lower OS [<a href="#rid64">64-66</a>]. Thrombocytopenia can be a dose-limiting toxicity, especially in heavily pretreated patients.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ixabepilone</strong> – <a class="drug drug_general" data-topicid="8909" href="/d/drug information/8909.html" rel="external">Ixabepilone</a> is an epothilone, a class of non-taxane tubulin polymerizing agents that have activity in taxane-resistant patients. As single-agent treatment, ixabepilone (40 mg/m<sup>2</sup> every 21 days) resulted in an ORR of 19 percent with a median duration of response of 5.7 months in a clinical trial [<a href="#rid67">67</a>]. Median OS was 8.6 months. Grade 3 and 4 peripheral sensory neuropathy occurred in 14 percent of patients.</p><p></p><p class="bulletIndent1">Some data suggest that <a class="drug drug_general" data-topicid="8909" href="/d/drug information/8909.html" rel="external">ixabepilone</a> may have less activity when compared with the taxanes, although it may be better tolerated. In the trial referenced above [<a href="#rid25">25</a>], weekly ixabepilone resulted in a shorter median PFS compared with taxanes (7.6 months versus 10 months with <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> and <a class="drug drug_general" data-topicid="10159" href="/d/drug information/10159.html" rel="external">nabpaclitaxel</a>) and OS (21 versus 26 and 27 months, respectively) but resulted in a lower incidence of hematologic toxicity (12 versus 21 and 51 percent) [<a href="#rid68">68</a>]. Of note, the incidence of serious (grade 3/4) sensory neuropathy was equivalent between ixabepilone and nabpaclitaxel (25 percent in both arms). Further results of CALGB 40502 are discussed above. (See <a class="local">'Comparing taxanes'</a> above.)</p><p></p><p class="bulletIndent1">In the presence of mild to moderate hepatic impairment, <a class="drug drug_general" data-topicid="8909" href="/d/drug information/8909.html" rel="external">ixabepilone</a> doses should be adjusted. Its usefulness in later line therapy is often limited by its toxicities of neuropathy, anemia, and fatigue. However, epothilones may cross the blood brain barrier [<a href="#rid69">69</a>], suggesting it may be an option for patients with central nervous system disease. (See  <a class="medical medical_review" href="/d/html/775.html" rel="external">"Brain metastases in breast cancer"</a>.)</p><p></p><p class="bulletIndent1">Despite US Food and Drug Administration approval, it is not available in Europe because the European Medicines Agency Committee for Medicinal Products for Human Use concluded that the benefit was marginal at best and the risk of peripheral neuropathy to be significant [<a href="#rid70">70</a>]. Alternate dosing schedules have also been reported.</p><p></p><p class="bulletIndent1">Given the large number of other options, we rarely use <a class="drug drug_general" data-topicid="8909" href="/d/drug information/8909.html" rel="external">ixabepilone</a> in our practice, and encourage clinical trial participation for our patients who have received all other available approved therapies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etoposide</strong> – Oral <a class="drug drug_general" data-topicid="8430" href="/d/drug information/8430.html" rel="external">etoposide</a> (50 mg/m<sup>2</sup> daily for 21 days every 28 days) is a later-line choice for patients with slow-growing disease who desire an oral agent. Etoposide has shown an ORR of 30 percent in pretreated patients, but may produce hematologic and gastrointestinal toxicity [<a href="#rid71">71-73</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Platinum agents</strong> – <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">Carboplatin</a> and <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> are rarely used as single agents in hormone receptor-positive metastatic breast cancer, although single-agent use in patients with germline mutations in breast cancer susceptibility genes 1 and 2 (<em>BRCA1</em> and <em>BRCA2</em>), or other homologous recombination deficiency is supported by clinical data. (See  <a class="medical medical_review" href="/d/html/14227.html" rel="external">"ER/PR negative, HER2-negative (triple-negative) breast cancer", section on 'Chemotherapy-naϊve patients, or those with progression on PARP inhibitors'</a>.)</p><p></p><p class="bulletIndent1">Available data suggest the response rate to <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> is higher among chemotherapy-naϊve patients rather than in patients who were previously treated (ORR 42 to 54 percent versus less than 10 percent, respectively) [<a href="#rid74">74</a>]. There is also interest in using these agents as part of a combination regimen. (See <a class="local">'Other regimens'</a> below.)</p><p></p><p class="bulletIndent1">Given the large number of other options, we rarely use single-agent platinums in our patients with hormone receptor-positive metastatic breast cancer, and encourage clinical trial participation for our patients who have received all other available approved therapies.</p><p></p><p class="headingAnchor" id="H1726404084"><span class="h1">SPECIAL CONSIDERATIONS FOR THOSE WITH RAPIDLY PROGRESSIVE DISEASE</span></p><p class="headingAnchor" id="H3035375503"><span class="h2">Combination chemotherapy versus endocrine therapy with targeted agents</span><span class="headingEndMark"> — </span>The choice between chemotherapy and endocrine therapy is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/767.html" rel="external">"Overview of the approach to metastatic breast cancer", section on 'Choosing between endocrine therapy and chemotherapy'</a>.)</p><p class="headingAnchor" id="H99380180"><span class="h2">Combination versus single agent chemotherapy</span><span class="headingEndMark"> — </span>Combination chemotherapy (rather than single-agent sequential therapy) may be appropriate when the higher chance of response is assessed to be more important than the potential for higher treatment toxicity, due to concerns about impending organ dysfunction from existing or rapidly progressing disease burden. However, both clinicians and patients should know there are no prospective data that show combination chemotherapy improves overall survival (OS) compared with single-agent sequential cytotoxic chemotherapy.</p><p>This was shown in the Eastern Cooperative Group 1193 trial, in which over 700 individuals were randomly assigned to <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> plus <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> (AP), doxorubicin, or paclitaxel. For those randomized to single-agent treatment, the protocol mandated cross over to the alternative agent at the time of disease progression. Treatment with AP resulted in:</p><p class="bulletIndent1"><span class="glyph">●</span>A higher overall response rate (ORR) compared with <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a> or to <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> (47 versus 36 and 34 percent)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A longer median time to progression (8 versus 6 and 6 months)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>However, there was no difference in OS (22 versus 19 and 22 months)</p><p></p><p>Although a 2009 meta-analysis that included 43 trials (n = 9742 individuals, 55 percent of whom were treated in the first-line setting) showed that combination therapy could improve OS relative to single-agent chemotherapy [<a href="#rid12">12</a>], these data are limited because they did not evaluate the benefits of combination chemotherapy compared with the <strong>sequential</strong><em> </em>administration of agents (eg, drug A plus B versus drug A then<em> </em>B).</p><p>There are few data to inform the benefits of combination chemotherapy in the second- or later-line setting. However, the use of a combination in a heavily pretreated patient may be warranted, particularly if a patient has a significant tumor burden, desires the best chance of a response, and is willing to accept the potentially significant risks of combination therapy.</p><p class="headingAnchor" id="H3847877248"><span class="h2">Combination chemotherapy regimens</span><span class="headingEndMark"> — </span>For patients in whom combination chemotherapy is chosen, available combination regimens are discussed below.</p><p class="headingAnchor" id="H99380304"><span class="h3">Anthracycline-containing regimens</span><span class="headingEndMark"> — </span>Anthracycline-based chemotherapy regimens are associated with response rates of up to 60 percent in previously untreated patients with metastatic breast cancer [<a href="#rid75">75-78</a>], although they are more toxic than sequential single-agent treatment or non-anthracycline-containing combinations [<a href="#rid48">48,79</a>].</p><p>Among the available regimens, an anthracycline plus taxane combination results in a higher response rate compared with non-taxane containing regimens. This was demonstrated in a meta-analysis of pooled individual patient data from eight trials (n = 3000) that compared anthracycline-containing regimens (without a taxane) with anthracycline plus taxane combinations [<a href="#rid80">80</a>]. Compared with non-taxane containing therapy, taxane plus anthracycline treatment resulted in a significantly higher ORR (57 versus 46 percent) and an improvement in the risk of disease progression (hazard ratio [HR] 0.92, 95% CI 0.85-0.99). Despite these results, there was no difference in median OS between anthracycline plus taxane versus anthracycline combinations that do not contain a taxane [<a href="#rid80">80</a>].</p><p>Examples of commonly used anthracycline-based combinations include (see  <a class="medical medical_review" href="/d/html/85677.html" rel="external">"Treatment protocols for breast cancer"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">Doxorubicin</a> plus <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> – ORR ranges from 47 to 54 percent [<a href="#rid81">81,82</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8663" href="/d/drug information/8663.html" rel="external">Epirubicin</a> with <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> and <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> – ORR ranges from 45 to 55 percent [<a href="#rid48">48,79</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">Doxorubicin</a>, <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a>, plus <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> – ORR 77 percent [<a href="#rid83">83</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">Doxorubicin</a> plus <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> or <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> – ORR is approximately 40 percent for either combination [<a href="#rid84">84</a>]</p><p></p><p class="headingAnchor" id="H99380311"><span class="h3">Non-anthracycline, taxane-based regimens</span><span class="headingEndMark"> — </span>For patients who are not suitable candidates for anthracyclines, taxane-based regimens can be administered. The choice among the taxanes is usually determined by the prior treatment history. Given the lack of complete cross-resistance between <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> and <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a>, we often will administer the alternative agent to the one used in the adjuvant setting (eg, if paclitaxel was used adjuvantly, docetaxel is used in the metastatic setting). For patients who are chemotherapy naïve, the choice between them should be based on individual considerations around each of their toxicity profiles.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gemcitabine</strong><strong> plus </strong><strong>paclitaxel</strong><strong> or </strong><strong>docetaxel</strong> – <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">Gemcitabine</a> (1250 mg/m<sup>2</sup> on days 1 and 8) plus <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> (175 mg/m<sup>2</sup> on day 1) resulted in an ORR of 41 percent when administered as a first-line therapy for metastatic breast cancer [<a href="#rid85">85</a>]. In a separate trial, gemcitabine (1000 mg/m<sup>2</sup> on days 1 and 8) plus <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> (75 mg/m<sup>2</sup> on day 1) resulted in an ORR of 43 percent in first-line therapy [<a href="#rid86">86</a>]. These two regimens have not been compared directly, but presumably gemcitabine plus docetaxel would have higher toxicity, given that both are myelotoxic as single agents.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Capecitabine</strong><strong> plus </strong><strong>docetaxel</strong> – <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">Capecitabine</a> (1250 mg/m<sup>2</sup>, twice daily for 14 of every 21 days) plus <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> (75 mg/m<sup>2</sup> every 21 days) (CD) resulted in an ORR of 42 percent [<a href="#rid87">87</a>]. Several studies also suggest it improves survival over single-agent docetaxel even when capecitabine was mandated on disease progression [<a href="#rid87">87,88</a>]. However, limited data suggest that CD is equivalent to <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> plus docetaxel but is the more toxic combination [<a href="#rid86">86</a>].</p><p></p><p class="headingAnchor" id="H99380339"><span class="h3">Other regimens</span><span class="headingEndMark"> — </span>For patients who are not candidates for anthracyclines or taxanes and those who have progressed despite prior treatment, there are several available alternate options. These are discussed below.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ixabepilone</strong><strong> plus </strong><strong>capecitabine</strong> – <a class="drug drug_general" data-topicid="8909" href="/d/drug information/8909.html" rel="external">Ixabepilone</a> (40 mg/m<sup>2</sup> every three weeks) plus <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> (1000 mg/m<sup>2</sup> twice daily for 14 of every 21 days) resulted in an ORR of 35 percent [<a href="#rid89">89</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cyclophosphamide</strong><strong>, </strong><strong>methotrexate</strong><strong>, and </strong><strong>fluorouracil</strong> – <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">Cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, and <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> (CMF) is rarely administered for metastatic breast cancer because it appears to produce the same response rate when compared with oral <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> (20 percent) in one trial [<a href="#rid90">90</a>]. However, CMF resulted in a shorter OS (median, 22 versus 18 months; HR 0.72, 95% CI 0.55-0.94). CMF may be indicated in patients who cannot tolerate capecitabine or for patients in whom an oral regimen is not feasible for whatever reason.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Combination regimens incorporating platinum salts</strong> – Regimens combining platinum salts with chemotherapies such as taxanes, <a class="drug drug_general" data-topicid="10046" href="/d/drug information/10046.html" rel="external">vinorelbine</a>, or <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> have been postulated to be specifically efficacious in tumors where DNA repair pathways are faulty.</p><p></p><p class="bulletIndent1">However, no prospective trials have been completed that demonstrate a survival advantage to such regimens compared with non-platinum regimens. We typically reserve platinum-containing combination regimens for those individuals with good performance status, but high disease burden, whose disease has progressed on other available chemotherapy agents [<a href="#rid91">91</a>].</p><p></p><p class="headingAnchor" id="H1241695742"><span class="h3">Avoidance of high-dose chemotherapy protocols</span><span class="headingEndMark"> — </span>High-dose chemotherapy with autologous stem cell transplantation is not an option for the standard treatment of metastatic breast cancer. A 2011 systematic review that included six randomized trials concluded that high-dose chemotherapy did not significantly improve OS and that any benefit from this treatment was minimal. Therefore, we advise against these treatments for metastatic breast cancer [<a href="#rid92">92</a>].</p><p class="headingAnchor" id="H454788256"><span class="h1">ADJUNCTIVE THERAPY</span><span class="headingEndMark"> — </span>The role of adjunctive therapy, such as pain medications and osteoclast inhibitors, in the treatment of patients with metastatic breast cancer is covered separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2815.html" rel="external">"Cancer pain management: Role of adjuvant analgesics (coanalgesics)"</a> and  <a class="medical medical_review" href="/d/html/2798.html" rel="external">"Cancer pain management: Use of acetaminophen and nonsteroidal anti-inflammatory drugs"</a> and  <a class="medical medical_review" href="/d/html/2814.html" rel="external">"Cancer pain management with opioids: Optimizing analgesia"</a> and  <a class="medical medical_review" href="/d/html/2792.html" rel="external">"Cancer pain management: General principles and risk management for patients receiving opioids"</a> and  <a class="medical medical_review" href="/d/html/14248.html" rel="external">"Interventional therapies for chronic pain"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/2801.html" rel="external">"Osteoclast inhibitors for patients with bone metastases from breast, prostate, and other solid tumors"</a>.)</p><p></p><p class="headingAnchor" id="H453567572"><span class="h1">DURATION OF TREATMENT</span><span class="headingEndMark"> — </span>Unlike in the adjuvant setting, there is no predetermined duration of treatment. Therefore, the duration of chemotherapy should be individualized taking into account the patient's goals of treatment, presence of treatment toxicities, and alternative options that might be available.</p><p class="bulletIndent1"><span class="glyph">●</span>In our experience, patients with endocrine-refractory, estrogen receptor (ER)-positive metastatic breast cancer rarely, if ever, have a complete clinical response to chemotherapy. For a patient with endocrine-refractory disease who is responding to treatment, we continue chemotherapy until the time of progression. However, for patients who experience side effects to treatment or prefer not to continue treatment for whatever reason, discontinuation of treatment is reasonable.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with ER-positive disease who are not known to be refractory to endocrine therapy, who received chemotherapy in the first line may consider switching to endocrine therapy for maintenance treatment.</p><p></p><p>For patients who respond to chemotherapy, some data suggest that there are benefits to continuing treatment beyond their best response (ie, maintenance therapy):</p><p class="bulletIndent1"><span class="glyph">●</span>A 2011 meta-analysis of first-line treatment randomized trials that included almost 2300 individuals compared maintenance treatment with treatment over a prespecified duration (range, three to eight cycles) [<a href="#rid93">93</a>]. Longer chemotherapy duration was associated with improvement in progression-free survival (PFS; hazard ratio [HR] 0.64, 95% CI 0.55-0.76) and overall survival (OS; HR 0.91, 95% CI 0.84-0.99).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A randomized trial published in 2013 consisted of 324 patients with metastatic breast cancer, all of whom were treated with <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> and <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> [<a href="#rid94">94</a>]. Patients who achieved disease control (complete or partial response, or stable disease) to treatment (n = 231) were randomly assigned to observation or maintenance chemotherapy with the same agents until disease progression.</p><p></p><p class="bulletIndent1">The administration of maintenance chemotherapy resulted in a higher PFS rate at six months compared with observation (60 versus 36 percent, respectively; HR 0.73, 95% CI 0.55-0.97) and improved OS (median, 32 versus 24 months; HR 0.65, 95% CI 0.42-0.99). However, continuation of <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> and <a class="drug drug_general" data-topicid="8487" href="/d/drug information/8487.html" rel="external">gemcitabine</a> resulted in a higher incidence of serious (grade 3/4) neutropenia (61 versus 0.9 percent) and grade 2/3 neuropathy (0.9 versus 0 percent).</p><p></p><p class="bulletIndent1">Despite these findings, several issues limit the universal application of these data in metastatic breast cancer:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Over 70 percent of patients in this study had hormone-positive breast cancer; of these patients, only approximately 20 percent of these individuals had received prior endocrine therapy and, for those in the control arm, endocrine therapy was not initiated after chemotherapy was discontinued.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The median age of participants was 48, suggesting that younger patients were preferentially enrolled.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The benefit in PFS was seen predominantly in the subgroup who were age &lt;50 years, had hormone receptor-negative disease, had responded to chemotherapy, and had visceral disease.</p><p></p><p>While these data support maintenance chemotherapy for individuals with metastatic breast cancer, it should not be considered a universal approach to the treatment of these patients, especially when one considers the biologic heterogeneity of breast cancer and the multiple ways that disease can be treated. However, in the setting of endocrine-refractory disease, the options other than chemotherapy are limited to observation or a clinical trial [<a href="#rid95">95</a>].</p><p class="headingAnchor" id="H3010243057"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113775.html" rel="external">"Society guideline links: Breast cancer"</a>.)</p><p class="headingAnchor" id="H2191622582"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Introduction</strong> – Despite the gains in early detection, up to 5 percent of individuals diagnosed with breast cancer have metastatic disease at the time of first presentation, designated "de novo"<em> </em>metastases. In addition, up to 30 percent of individuals with early-stage, non-metastatic breast cancer at diagnosis will develop distant metastatic disease. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Goals of treatment and general approach</strong> – The goals of treatment of metastatic breast cancer are to prolong survival and improve quality of life by reducing cancer-related symptoms. In order to achieve these goals an individualized approach is needed since no one strategy can be applied for all individuals. (See <a class="local">'Goals of treatment and definitions'</a> above.)</p><p></p><p class="bulletIndent1">Although endocrine therapy is typically employed for patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer (particularly in the initial treatment setting), cytotoxic chemotherapy may be used to achieve these goals in select patients (eg, those presenting with rapid disease progression following more than one endocrine therapy or disease that is refractory to multiple lines of endocrine therapy). (See  <a class="medical medical_review" href="/d/html/767.html" rel="external">"Overview of the approach to metastatic breast cancer", section on 'Choosing between endocrine therapy and chemotherapy'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Choice of chemotherapy</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with hormone receptor-positive, HER2-negative metastatic breast cancer that is refractory to endocrine therapy, we suggest single-agent chemotherapy administered sequentially rather than combination chemotherapy (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Tumor burden'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>However, for select patients with symptomatic disease due to the location of specific metastatic lesions and a large tumor burden, a combination regimen rather than a single-agent is more appropriate. Combination therapy results in a greater likelihood of a response compared with single-agent therapy, which may be of a sufficient benefit to justify the risks of treatment. (See <a class="local">'Combination versus single agent chemotherapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Subsequent line options</strong> – For second- and third-line chemotherapy, two antibody-drug conjugates have recently been shown to be more effective than other available chemotherapies, <a class="drug drug_general" data-topicid="126410" href="/d/drug information/126410.html" rel="external">fam-trastuzumab deruxtecan</a>, in HER2-"low" tumors, and <a class="drug drug_general" data-topicid="127999" href="/d/drug information/127999.html" rel="external">sacituzumab govitecan</a>. (See <a class="local">'Subsequent line options'</a> above and  <a class="medical medical_review" href="/d/html/767.html" rel="external">"Overview of the approach to metastatic breast cancer", section on 'HER2-low tumors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring therapy</strong> – Careful assessment for response to treatment requires serial clinical examination, repeat laboratory evaluation (including tumor markers), and radiographic imaging. (See <a class="local">'Monitoring therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Duration of treatment</strong> – Unlike in the adjuvant setting, there is no predetermined duration of treatment. For a patient with endocrine-refractory disease who is responding to treatment, we continue chemotherapy until the time of progression. However, for patients who experience side effects to treatment or prefer not to continue treatment for whatever reason, discontinuation of treatment is reasonable. (See <a class="local">'Duration of treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition of treatment failure</strong> – Some criteria that we use to define treatment failure include any of the following: clinical deterioration during treatment (ie, increasing disease-related symptoms, intolerable treatment toxicity, a decline in performance status), appearance of new metastases, and increasing size of previously documented metastatic lesions. (See <a class="local">'Definition of treatment failure'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Breast Cancer. http://www.cancerresearchuk.org/cancer-info/cancerstats/world/breast-cancer-world/ (Accessed on March 04, 2013).</li><li><a class="nounderline abstract_t">Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687.</a></li><li><a class="nounderline abstract_t">Chia SK, Speers CH, D'yachkova Y, et al. The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 2007; 110:973.</a></li><li><a class="nounderline abstract_t">Gennari A, Conte P, Rosso R, et al. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 2005; 104:1742.</a></li><li><a class="nounderline abstract_t">Dafni U, Grimani I, Xyrafas A, et al. Fifteen-year trends in metastatic breast cancer survival in Greece. Breast Cancer Res Treat 2010; 119:621.</a></li><li><a class="nounderline abstract_t">Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. Arch Pathol Lab Med 2020; 144:545.</a></li><li><a class="nounderline abstract_t">Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. J Clin Oncol 2020; 38:1346.</a></li><li><a class="nounderline abstract_t">Wolff AC, Hammond MEH, Allison KH, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Arch Pathol Lab Med 2018; 142:1364.</a></li><li><a class="nounderline abstract_t">Wolff AC, Hammond MEH, Allison KH, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol 2018; 36:2105.</a></li><li><a class="nounderline abstract_t">Wilcken N, Hornbuckle J, Ghersi D. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev 2003; :CD002747.</a></li><li><a class="nounderline abstract_t">Dear RF, McGeechan K, Jenkins MC, et al. Combination versus sequential single agent chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2013; :CD008792.</a></li><li><a class="nounderline abstract_t">Carrick S, Parker S, Thornton CE, et al. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2009; :CD003372.</a></li><li><a class="nounderline abstract_t">Smith IC, Heys SD, Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002; 20:1456.</a></li><li><a class="nounderline abstract_t">Byrski T, Dent R, Blecharz P, et al. Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res 2012; 14:R110.</a></li><li><a class="nounderline abstract_t">Pritchard KI, Paterson AH, Paul NA, et al. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol 1996; 14:2731.</a></li><li><a class="nounderline abstract_t">Fossati R, Confalonieri C, Torri V, et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1998; 16:3439.</a></li><li><a class="nounderline abstract_t">Mauri D, Kamposioras K, Tsali L, et al. Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis. Cancer Treat Rev 2010; 36:69.</a></li><li><a class="nounderline abstract_t">Sparano JA, Wang M, Martino S, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358:1663.</a></li><li><a class="nounderline abstract_t">Piccart MJ, Klijn J, Paridaens R, et al. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 1997; 15:3149.</a></li><li><a class="nounderline abstract_t">Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008; 26:1642.</a></li><li><a class="nounderline abstract_t">Ibrahim NK, Samuels B, Page R, et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 2005; 23:6019.</a></li><li><a class="nounderline abstract_t">Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23:7794.</a></li><li><a class="nounderline abstract_t">Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009; 27:3611.</a></li><li><a class="nounderline abstract_t">Jones SE, Erban J, Overmoyer B, et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005; 23:5542.</a></li><li><a class="nounderline abstract_t">Rugo HS, Barry WT, Moreno-Aspitia A, et al. Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance). J Clin Oncol 2015; 33:2361.</a></li><li><a class="nounderline abstract_t">Khan QJ, Bohnenkamp C, Monson T, et al. Randomized trial of fixed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer: The X-7/7 trial. J Clin Oncol 2023; 41S:ASCO #1007.</a></li><li><a class="nounderline abstract_t">Kopf B, De Giorgi U, Zago S, et al. Innovative therapy for patients with brain metastases: oral treatments. J Chemother 2004; 16 Suppl 5:94.</a></li><li><a class="nounderline abstract_t">Fumoleau P, Largillier R, Clippe C, et al. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 2004; 40:536.</a></li><li><a class="nounderline abstract_t">Oshaughnessy JA, Blum J, Moiseyenko V, et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001; 12:1247.</a></li><li><a class="nounderline abstract_t">Amstutz U, Henricks LM, Offer SM, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther 2018; 103:210.</a></li><li><a class="nounderline abstract_t">Hertz DL, McShane LM, Hayes DF. Defining Clinical Utility of Germline Indicators of Toxicity Risk: A Perspective. J Clin Oncol 2022; 40:1721.</a></li><li><a class="nounderline abstract_t">Lee AM, Shi Q, Pavey E, et al. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). J Natl Cancer Inst 2014; 106.</a></li><li><a class="nounderline abstract_t">Rai K, Batukbhai BDO, Brooks GA. Risk of treatment-related death in carriers of pathogenic DPYD polymorphisms treated with fluoropyrimidine chemotherapy: A systematic review and patient-level analysis. J Clin Oncol 2019; 37S: ASCO #e15132.</a></li><li><a class="nounderline abstract_t">Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228.</a></li><li><a class="nounderline abstract_t">Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med 2022; 387:9.</a></li><li><a class="nounderline abstract_t">Tarantino P, Viale G, Press MF, et al. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Ann Oncol 2023; 34:645.</a></li><li><a class="nounderline abstract_t">Mosele F, Deluche E, Lusque A, et al. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat Med 2023; 29:2110.</a></li><li><a class="nounderline abstract_t">Fernandez AI, Liu M, Bellizzi A, et al. Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue. JAMA Oncol 2022; 8:1.</a></li><li><a class="nounderline abstract_t">Moutafi M, Robbins CJ, Yaghoobi V, et al. Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer. Lab Invest 2022; 102:1101.</a></li><li class="breakAll">TRODELVY® (sacituzumab govitecan-hziy) for injection, for intravenous use. US Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761115s035lbl.pdf (Accessed on February 06, 2023).</li><li><a class="nounderline abstract_t">Moy B, Rumble RB, Carey LA, Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor–Negative Metastatic Breast Cancer Expert Panel. Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update. J Clin Oncol 2023; 41:1318.</a></li><li><a class="nounderline abstract_t">Gradishar WJ, Moran MS, Abraham J, et al. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2022; 20:691.</a></li><li><a class="nounderline abstract_t">Rugo H, Bardia A, Marme F, et al. Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer. J Clin Oncol 2022; LBA1001.</a></li><li><a class="nounderline abstract_t">Rugo HS, Bardia A, Marmé F, et al. Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. J Clin Oncol 2022; 40:3365.</a></li><li><a class="nounderline abstract_t">Rugo HS, Bardia A, Marmé F, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet 2023; 402:1423.</a></li><li><a class="nounderline abstract_t">Andersson M, Daugaard S, von der Maase H, Mouridsen HT. Doxorubicin versus mitomycin versus doxorubicin plus mitomycin in advanced breast cancer: a randomized study. Cancer Treat Rep 1986; 70:1181.</a></li><li><a class="nounderline abstract_t">Norris B, Pritchard KI, James K, et al. Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. J Clin Oncol 2000; 18:2385.</a></li><li><a class="nounderline abstract_t">Joensuu H, Holli K, Heikkinen M, et al. Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial. J Clin Oncol 1998; 16:3720.</a></li><li><a class="nounderline abstract_t">Ejlertsen B, Mouridsen HT, Langkjer ST, et al. Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403). J Clin Oncol 2004; 22:2313.</a></li><li><a class="nounderline abstract_t">Nielsen D, Dombernowsky P, Larsen SK, et al. Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study. Cancer Chemother Pharmacol 2000; 46:459.</a></li><li><a class="nounderline abstract_t">O'Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004; 15:440.</a></li><li><a class="nounderline abstract_t">Keller AM, Mennel RG, Georgoulias VA, et al. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol 2004; 22:3893.</a></li><li><a class="nounderline abstract_t">Swain SM. Adult multicenter trials using dexrazoxane to protect against cardiac toxicity. Semin Oncol 1998; 25:43.</a></li><li><a class="nounderline abstract_t">Blank N, Laskov I, Kessous R, et al. Absence of cardiotoxicity with prolonged treatment and large accumulating doses of pegylated liposomal doxorubicin. Cancer Chemother Pharmacol 2017; 80:737.</a></li><li><a class="nounderline abstract_t">Manso L, Moreno Antón F, Izarzugaza Perón Y, et al. Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study. Breast J 2019; 25:219.</a></li><li><a class="nounderline abstract_t">Kaufman PA, Awada A, Twelves C, et al. Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2015; 33:594.</a></li><li><a class="nounderline abstract_t">Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011; 377:914.</a></li><li><a class="nounderline abstract_t">Yuan P, Hu X, Sun T, et al. Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial. Eur J Cancer 2019; 112:57.</a></li><li><a class="nounderline abstract_t">Vogel C, O'Rourke M, Winer E, et al. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol 1999; 10:397.</a></li><li><a class="nounderline abstract_t">Martín M, Ruiz A, Muñoz M, et al. Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial. Lancet Oncol 2007; 8:219.</a></li><li><a class="nounderline abstract_t">Fumoleau P, Delgado FM, Delozier T, et al. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol 1993; 11:1245.</a></li><li><a class="nounderline abstract_t">Jones S, Winer E, Vogel C, et al. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 1995; 13:2567.</a></li><li><a class="nounderline abstract_t">Gridelli C, Perrone F, Gallo C, et al. Single-agent gemcitabine as second-line treatment in patients with advanced non small cell lung cancer (NSCLC): a phase II trial. Anticancer Res 1999; 19:4535.</a></li><li><a class="nounderline abstract_t">Rha SY, Moon YH, Jeung HC, et al. Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Breast Cancer Res Treat 2005; 90:215.</a></li><li><a class="nounderline abstract_t">Blackstein M, Vogel CL, Ambinder R, et al. Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology 2002; 62:2.</a></li><li><a class="nounderline abstract_t">Feher O, Vodvarka P, Jassem J, et al. First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study. Ann Oncol 2005; 16:899.</a></li><li><a class="nounderline abstract_t">Perez EA, Lerzo G, Pivot X, et al. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007; 25:3407.</a></li><li><a class="nounderline abstract_t">Rugo RS, Barry WT, Moreno-Aspitia A, et al. CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel compared to weekly nanoparticle albumin bound nab-paclitaxel or ixabepilone with or without bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. J Clin Oncol 2012; 30S: ASCO #CRA1002.</a></li><li><a class="nounderline abstract_t">Brunden KR, Ballatore C, Lee VM, et al. Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies. Biochem Soc Trans 2012; 40:661.</a></li><li class="breakAll">European Medicines Agency Committee for Medicinal Products for Human Use. Recommendation for refusal of marketing authorization for ixabepilone. http://www.esmo.org/no_cache/view-news.html?tx_ttnews[tt_news]=480&amp;tx_ttnews[backPid]=585&amp;cHash=9385b0342b (Accessed on September 21, 2017).</li><li><a class="nounderline abstract_t">Martín M, Lluch A, Casado A, et al. Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer. J Clin Oncol 1994; 12:986.</a></li><li><a class="nounderline abstract_t">Pusztai L, Walters RS, Valero V, et al. Daily oral etoposide in patients with heavily pretreated metastatic breast cancer. Am J Clin Oncol 1998; 21:442.</a></li><li><a class="nounderline abstract_t">Saphner T, Weller EA, Tormey DC, et al. 21-day oral etoposide for metastatic breast cancer: a phase II study and review of the literature. Am J Clin Oncol 2000; 23:258.</a></li><li><a class="nounderline abstract_t">Isakoff SJ. Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J 2010; 16:53.</a></li><li><a class="nounderline abstract_t">Hortobagyi GN, Bodey GP, Buzdar AU, et al. Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. J Clin Oncol 1987; 5:354.</a></li><li><a class="nounderline abstract_t">Falkson G, Tormey DC, Carey P, et al. Long-term survival of patients treated with combination chemotherapy for metastatic breast cancer. Eur J Cancer 1991; 27:973.</a></li><li><a class="nounderline abstract_t">Coombes RC, Bliss JM, Wils J, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group. J Clin Oncol 1996; 14:35.</a></li><li><a class="nounderline abstract_t">Blomqvist C, Elomaa I, Rissanen P, et al. Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: a randomized trial comparing weekly and every-4-week administration. J Clin Oncol 1993; 11:467.</a></li><li><a class="nounderline abstract_t">A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group. J Clin Oncol 1991; 9:305.</a></li><li><a class="nounderline abstract_t">Piccart-Gebhart MJ, Burzykowski T, Buyse M, et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol 2008; 26:1980.</a></li><li><a class="nounderline abstract_t">Nabholtz JM, Falkson C, Campos D, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 2003; 21:968.</a></li><li><a class="nounderline abstract_t">Biganzoli L, Cufer T, Bruning P, et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. J Clin Oncol 2002; 20:3114.</a></li><li><a class="nounderline abstract_t">Nabholtz JM, Mackey JR, Smylie M, et al. Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer. J Clin Oncol 2001; 19:314.</a></li><li><a class="nounderline abstract_t">Cassier PA, Chabaud S, Trillet-Lenoir V, et al. A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study. Breast Cancer Res Treat 2008; 109:343.</a></li><li><a class="nounderline abstract_t">Albain KS, Nag SM, Calderillo-Ruiz G, et al. Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 2008; 26:3950.</a></li><li><a class="nounderline abstract_t">Chan S, Romieu G, Huober J, et al. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol 2009; 27:1753.</a></li><li><a class="nounderline abstract_t">O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20:2812.</a></li><li><a class="nounderline abstract_t">Soto C, Torrecillas L, Reyes S, et al. Capecitabine (X) and taxanes in patients (pts) with anthracycline-pretreated metastatic breast cancer (MBC): Sequential versus combined therapy results from a MOSG randomized phase III trial. J Clin Oncol 2006; 24S: ASCO #570.</a></li><li><a class="nounderline abstract_t">Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007; 25:5210.</a></li><li><a class="nounderline abstract_t">Stockler MR, Harvey VJ, Francis PA, et al. Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J Clin Oncol 2011; 29:4498.</a></li><li><a class="nounderline abstract_t">Carrick S, Ghersi D, Wilcken N, Simes J. Platinum containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 2004; :CD003374.</a></li><li><a class="nounderline abstract_t">Berry DA, Ueno NT, Johnson MM, et al. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials. J Clin Oncol 2011; 29:3224.</a></li><li><a class="nounderline abstract_t">Gennari A, Stockler M, Puntoni M, et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol 2011; 29:2144.</a></li><li><a class="nounderline abstract_t">Park YH, Jung KH, Im SA, et al. Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02. J Clin Oncol 2013; 31:1732.</a></li><li><a class="nounderline abstract_t">Seidman AD. The search for an elusive uniform strategy for a heterogeneous disease: lesson learned? J Clin Oncol 2013; 31:1707.</a></li></ol></div><div id="topicVersionRevision">Topic 83848 Version 42.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="http://www.cancerresearchuk.org/cancer-info/cancerstats/world/breast-cancer-world/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Breast Cancer. http://www.cancerresearchuk.org/cancer-info/cancerstats/world/breast-cancer-world/ (Accessed on March 04, 2013).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15894097" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17647245" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16149088" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19915976" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Fifteen-year trends in metastatic breast cancer survival in Greece.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31928354" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31928404" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29846104" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29846122" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12804433" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24347031" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Combination versus sequential single agent chemotherapy for metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19370586" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Single agent versus combination chemotherapy for metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11896092" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22817698" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8874334" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9779724" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19945225" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18420499" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Weekly paclitaxel in the adjuvant treatment of breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9294478" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18375893" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16135470" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16172456" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19470941" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16110015" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26056183" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Randomized trial of fixed dose capecitabine compared to standard dose capecitabine in metastatic breast cancer: The X-7/7 trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15675490" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Innovative therapy for patients with brain metastases: oral treatments.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14962720" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11697835" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29152729" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35324346" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Defining Clinical Utility of Germline Indicators of Toxicity Risk: A Perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25381393" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Risk of treatment-related death in carriers of pathogenic DPYD polymorphisms treated with fluoropyrimidine chemotherapy: A systematic review and patient-level analysis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19097774" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35665782" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37269905" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37488289" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35113160" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Examination of Low ERBB2 Protein Expression in Breast Cancer Tissue.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35595825" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35595825" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36626701" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Chemotherapy and Targeted Therapy for Endocrine-Pretreated or Hormone Receptor-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35714673" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36027558" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37633306" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3530444" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Doxorubicin versus mitomycin versus doxorubicin plus mitomycin in advanced breast cancer: a randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10856098" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9850014" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15197192" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group Trial (SBG9403).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11138459" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Epirubicin or epirubicin and cisplatin as first-line therapy in advanced breast cancer. A phase III study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14998846" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15459210" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9768823" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Adult multicenter trials using dexrazoxane to protect against cardiac toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28801766" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Absence of cardiotoxicity with prolonged treatment and large accumulating doses of pegylated liposomal doxorubicin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30734437" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25605862" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21376385" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30928806" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Eribulin mesilate versus vinorelbine in women with locally recurrent or metastatic breast cancer: A randomised clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10370781" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17329192" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8315421" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7595708" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10650806" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Single-agent gemcitabine as second-line treatment in patients with advanced non small cell lung cancer (NSCLC): a phase II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15830134" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11810037" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15821120" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : First-line gemcitabine versus epirubicin in postmenopausal women aged 60 or older with metastatic breast cancer: a multicenter, randomized, phase III study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17606974" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : CALGB 40502/NCCTG N063H: Randomized phase III trial of weekly paclitaxel compared to weekly nanoparticle albumin bound nab-paclitaxel or ixabepilone with or without bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22817712" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22817712" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Brain-penetrant microtubule-stabilizing compounds as potential therapeutic agents for tauopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8164052" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9781596" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Daily oral etoposide in patients with heavily pretreated metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10857889" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : 21-day oral etoposide for metastatic breast cancer: a phase II study and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20164691" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Triple-negative breast cancer: role of specific chemotherapy agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3819804" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1832906" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Long-term survival of patients treated with combination chemotherapy for metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8558217" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8445422" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: a randomized trial comparing weekly and every-4-week administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1988577" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18421049" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12637459" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12118025" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11208821" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17611792" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : A phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18711184" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19273714" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12065558" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Capecitabine (X) and taxanes in patients (pts) with anthracycline-pretreated metastatic breast cancer (MBC): Sequential versus combined therapy results from a MOSG randomized phase III trial</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17968020" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22025143" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15266482" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Platinum containing regimens for metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21768454" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21464403" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23569309" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23569322" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : The search for an elusive uniform strategy for a heterogeneous disease: lesson learned?</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
